Over the past five years, the cosmetic industry has met with several legislative changes. Within the new legislative package, including the new REACH and CLP, it is important to find a comfortable routine that will minimize costs while staying effective and compliant with all regulations.
5 Changes in Signal Detection Management
The European Medicines Agency, regulatory authorities in the Member States and marketing authorisation holders are responsible for detecting and managing safety signals. A safety signal is generally defined as information about a new or known Adverse Event that may have been caused by a medicine, where it is therefore necessary to conduct further investigation. Evaluation of safety signals plays a major role within pharmacovigilance. Therefore, it is vital for regulatory authorities to know the latest updates detailing the risks and benefits of medicines. The EudraVigilance database is an important source of information on suspected adverse reactions and signals.
What changes can we expect?
The latest update to the guidance of routine signal detection methods used by the EMA, regulatory authorities of the Member States and marketing authorisation holders was published in December 2016. This guidance only provides discussion on the recommended methods for screening for adverse reactions.
In August 2016, the European Commission published a three-year report on pharmacovigilance tasks by Member States and EMA, containing key activities undertaken during the reporting period, a high-level description of the EU pharmacovigilance system, the key achievements of recent years, as well as ways for future improvement.
Regulatory requirements are set in GVP Module IX on signal management. Public consultations on GVP Module IX – Signal management (Rev 1) and revised guidance on statistical methods (addendum I) ended in October 2016. Its anticipated date for coming into effect is Q1 2017. Revision 1 includes major modifications based on experience gained over the past four years.
What are the major changes Revision 1 will bring?
1. There are strict timelines for safety review for types of products and maximum timelines for signal approaches based upon the type of product.
2. In 2017, the EudraVigilance database will be made available to all Companies. Signal detection using this system for quantitative analyses will be mandatory.
3. To ensure people are trained in these aspects, there will be training courses operating for people to attend and pass a test to use the database.
4. There will be a new mechanism in place to alert Regulators when a signal is identified.
5. There will be strict timelines applied for licence variations based upon the level of patient risk identified from the signal assessment. The maximum will again be three months. Urgent safety restrictions: 48 hours. Other timelines are set at one month.
For more information on signal detection and management, visit our website.
Interested in this topic?
Advanced Protein Aggregation & Characterization
This training will focus on occurrence of particles in drug products, effects of protein aggregates, critical process and parameters. Attendees will gain overview of on utility and limits of predictive experiments, learn concerns from the authorities and relevant aggregation guidelines, and more.
Corporate Compliance & Transparency in the Pharmaceutical Industry
This two-day conference will serve as a platform for an open and dynamic dialogue with HCPs and patients to achieve common goals. Learn how to embed compliance in the business and develop one simple system for managing compliance & transparency in a complex and regulated environment.
Quality in Pharma & Biotech
Join the senior quality experts & regulators to understand how to close the loop in your desired level of quality. Gain critical insights into new regulatory expectations, process simplification and robustness, lean six sigma, MHRA & FDA inspection approach and reach higher quality effectively.